

## Who Should Be Tested?

**Women with  
unexplained infertility**

**Women with unexpected  
IVF failure**

**Women with limited  
embryo reserves**

**Women experiencing recurrent  
pregnancy loss**

## What physicians are saying about ReceptivaDx testing

"ReceptivaDx™ provides unique information for our patients with unexplained infertility, failed IVF history and those with recurrent pregnancy loss. In the past, so many of these patients would simply give up. The test has made a significant difference for our practice."

**Sunny Jun, MD - CCRM San Francisco  
Menlo Park, CA**

"ReceptivaDx has given me insight into previously unexplained infertility and failed IVF along with treatment options for my patients."

**Mira Aubuchon, M.D. - MCRM Fertility  
Chesterfield, Missouri**

"Endometriosis/uterine receptivity defects are common and in this 'no laparoscopy' era, ReceptivaDx is essential for diagnosis and treatment planning."

**Alex Steinleitner, M.D. Physician - Central Coast Fertility  
San Luis Obispo, CA**

## Getting Tested

Over 430 Fertility Centers in the US offer ReceptivaDx. In addition to fertility centers listed on our website, patients can request a collection kit for future testing at a fertility center or Ob-Gyn office near them. Everything needed to properly submit a sample is included in the kit. Please call our customer service desk at 800-795-5385 for further assistance.

## Sample Requirements

An endometrial biopsy is collected during the window of implantation in either a natural cycle or controlled "mock cycle". Accurate biopsy timing is important to the quality of results.

Natural Cycle: 7-10 days after ovulation

Mock Cycle: 5-10 days after start of progesterone

## Cost of Testing

A complete pathology report and interpretation of the BCL6 marker is \$690 US dollars. Optional testing to rule out endometritis, can be added to your ReceptivaDx panel for an additional \$145 dollars. Overnight shipping via FedEx from within the US is also covered in the cost. International customers are eligible for US pricing, but must arrange shipping at their own expense. Payment is required at the time of testing before any sample can be processed. A detailed receipt will be provided to patients to help with reimbursement from insurance or healthcare spending accounts. CiceroDx does not contract with or bill insurance.

## Test Results

Results are faxed to referring physicians 7-10 days from date our lab receives the sample. We cannot provide patients with results or copies of their reports. Please contact your physician if a copy is desired.

## Cicero Diagnostics

**Is the exclusive provider of  
ReceptivaDx (BCL6 Analysis)**

*Cicero Diagnostics  
is dedicated to the transfer of  
new technologies to advance global  
healthcare for women.*

[www.receptivadx.com](http://www.receptivadx.com)

**(800) 795-5385**



## Patient Information

### BCL6 Endometrial Biopsy Analysis



***Resolving Barriers  
to a Successful Pregnancy***

***Detection of Uterine  
Inflammation & Progesterone  
Resistance***

# What is ReceptivaDx?

ReceptivaDx detects inflammation on the uterine lining, a sign of previously undetected endometriosis. The test can also detect recurring endometriosis in patients previously diagnosed and treated for the condition.

Endometriosis is considered to be the leading cause of unexplained infertility, IVF transfer failure and recurrent pregnancy loss.

ReceptivaDx provides new answers and new treatment pathways even when genetic testing of embryos and attempts to define optimal transfer windows have failed to yield a successful pregnancy.

Based on an endometrial biopsy, ReceptivaDx measures a protein called BCL6. Validation studies demonstrated a 93% sensitivity and 96% specificity between a positive BCL6 result and a confirmed diagnosis of endometriosis.

## INCIDENCE RATE OF POSITIVE BCL6 RESULTS IN WOMEN WITH IVF FAILURE HISTORY

IVF FAILURE HISTORY	% BCL6 POSITIVE
0 Transfer Attempts	41%
1 – 2 Transfer Attempts	62%
3 - 4 Transfer Attempts	81%
5 + Transfer Attempts	84%

"Women testing positive for BCL6 are 5 times less likely to succeed in IVF than women with a negative test result."



Bruce Lessey, M.D., Ph.D.


Scientific Advisor  
CiceroDx, Inc.

# What do my ReceptivaDx test results mean and what treatment options are available?

- **If negative for BCL6**, women can be confident that endometriosis is not the underlying issue and future IVF success rates will be consistent with the general IVF patient population.
- **If positive for BCL6**, inflammation on the uterine lining is the likely cause of implantation failure. This inflammation is most often caused by the body's immune response to previously undetected endometriosis.
- A treatment plan involving hormone therapy or laparoscopy to suppress or remove visible endometriosis can correct the situation.
- In a recent clinical study\*, BCL6 positive patients undergoing 60 days of hormone suppression therapy or laparoscopic surgery demonstrated excellent success on their next transfer attempt (see graph below).
- Risk of miscarriage was dramatically reduced in patients receiving treatment when compared to women in the control group that did not receive treatment after a positive BCL6 result.

## Treatment Outcome Comparisons of BCL6 Positive Patients

Hormone Suppression Therapy (Depot Lupron) vs Laparoscopy vs Control Group (No treatment)



\* Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression - Journal of Assisted Reproduction & Genetics 2019 Jan 4

"We were losing all hope until we did the ReceptivaDx test. After we did it, we finally had an answer and a way forward. What I wouldn't give to have been able to do it sooner." -Andrea P.